Originally published on Technavio:Cell Culture Market Forecast 2023-2027 North America, Europe, EMEA, APAC - US, Canada, China, Germany, UK

The Cell Culture Market:
The estimated growth of the Cell Culture Market is USD 17.74 billion at a Compound Annual Growth Rate (CAGR) of 11.3% between 2022 and 2027. Derived from biological entities, biopharmaceuticals, including vaccines, stem cells, gene therapies, and antibodies, are at the forefront of therapeutic product development. Stem cell-based regenerative medicine, leveraging indefinite division and differentiation capabilities, shows promise in addressing severe chronic ailments. Biopharmaceutical companies are advancing production technologies, particularly cell culture, to meet the growing demand for mammalian cell-derived products, exemplified by the success of monoclonal antibodies such as Humira and Rituxan, enhancing treatment efficacy and market growth.

Market Dynamics:
The comprehensive report, based on data from 2022, highlights key drivers, trends, and challenges. A holistic analysis of drivers enables companies to refine marketing strategies for a competitive advantage.

Market Drivers:
The substantial potential in emerging regions, notably India, China, and South Africa, is a significant driver for market growth. These countries are experiencing rapid growth in pharmaceutical and biotechnology infrastructure, fostering technology and healthcare facilities. Manufacturers are expanding production facilities in these regions due to lower costs and favorable initiatives. For example, Thermo Fisher Scientific actively pursues opportunities in emerging markets like China and India, raising awareness and adoption of advanced technologies like cell culture, expanding vendor presence, and fueling market share.

Market Trends:
A noteworthy trend is the increasing demand for monoclonal antibodies, which have diverse applications in biology, diagnostics, and medicine, addressing conditions such as cancer, multiple sclerosis, and cardiovascular disease. The rising demand for monoclonal antibodies spurs the development of advanced production technologies. With the prevalence of chronic diseases, the need for antibody treatments is rising. Leading manufacturers like Thermo Fisher Scientific are expanding production facilities with multiple bioreactors, utilizing cutting-edge platforms, single-use methods, and rapid contamination tests for antibody production. This growing demand for monoclonal antibodies is expected to drive the market size by increasing the need for equipment and consumables.

Market Challenge:
The market faces a significant challenge due to the expensive nature of equipment, which includes consumables and equipment. Consumables, being more cost-effective, contrast with the substantial expenses associated with equipment like CO2 incubators, bioreactors, cryostorage systems, and biosafety cabinets. High acquisition and maintenance costs, coupled with meticulous attention and regular maintenance requirements, may deter adoption rates, impacting market growth in the forecasted period.

Key Customer Landscape:
The market growth analysis includes the adoption lifecycle, covering from the innovator’s stage to the laggard’s stage, and focuses on adoption rates in different regions based on penetration. The report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop growth strategies.

Market Segmentation:
The consumables segment is expected to contribute significantly to market growth during the forecast period, being the largest revenue-generating segment. Consumables, including sera, media, and reagents, have high availability, vast applicability, and repeated usage. The consumables segment, valued at USD 8.03 billion in 2017, continued to grow until 2021, driven by the rising demand for cell-based research and therapies. The low price of consumables and increased investments in R&D by companies further fuel market growth.

Regional Analysis:
North America is estimated to contribute 39% to the global market growth during the forecast period. The presence of major companies, such as Thermo Fisher Scientific, and investments in new manufacturing facilities equipped with bioprocessing units and necessary equipment for cell culture, are significant factors accelerating regional growth. Research on stem cells and cancer is likely to propel market growth, with an increase in cancer cases driving the need for cell-based therapies and vaccines. Additionally, the presence of sophisticated healthcare manufacturing facilities is expected to fuel demand, increasing product offerings and visibility in the region.

Major Companies:
Companies are implementing various strategies, including strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. Notable companies include FUJIFILM Holdings Corp, focusing on cell culture.

To Learn deeper into this report , View Sample PDF
The global cell culture market is witnessing exponential growth driven by advancements in cell culture techniques and substrates, especially in biopharmaceutical development and vaccine production. Researchers are harnessing cell-based models and organoids for therapeutic and diagnostic tools, with high-throughput screening platforms accelerating drug discovery. Cell culture-based vaccine production, targeting contagious viruses, is on the rise, with European countries leading in biopharmaceutical production.
The market forecasting report predicts growth by revenue at global, regional, and country levels, providing an analysis of the latest trends and growth opportunities from 2017 to 2027.

For more information please contact.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com/